- Home
- BBU vs DNLI Comparison
BBU vs DNLI Comparison
Compare BBU & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBU | DNLI |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BBU | DNLI |
|---|---|---|
| Price | $35.41 | $16.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $34.67 | $32.58 |
| AVG Volume (30 Days) | 52.4K | ★ 1.8M |
| Earning Date | 01-30-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,790,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.85 | $3,993.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.63 | $10.57 |
| 52 Week High | $36.90 | $24.35 |
Technical Indicators
Market Signals| Indicator | BBU | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 43.71 |
| Support Level | $34.82 | $16.66 |
| Resistance Level | $36.46 | $18.30 |
| Average True Range (ATR) | 1.13 | 1.01 |
| MACD | -0.07 | -0.36 |
| Stochastic Oscillator | 21.22 | 5.57 |
Price Performance
Historical ComparisonAbout BBU Brookfield Business Partners L.P. Limited Partnership Units
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.